Masimo CEO Says Users Are Better Off Without Apple’s Blood Oxygen Tool
- Kiani says he hasn’t discussed settling with Apple executives
- Apple disputes Masimo’s claims that its feature is innaccurate
Joe Kiani
Photographer: Michael Nagle/BloombergThis article is for subscribers only.
Masimo Corp. Chief Executive Officer Joe Kiani, waging a legal fight with Apple Inc. over a blood oxygen feature, said that consumers are better off without the iPhone maker’s version of the technology.
The remarks followed Apple’s decision to cease sales of smartwatches Thursday that had the tool — a gauge of blood oxygen saturation known as a pulse oximeter — which had been a heavily marketed health feature on the devices. The move stemmed from a ruling by the US International Trade Commission that found the technology violated Masimo patents.